FDA Boots 15 Forgotten Drugs from Approval List Cleanly
Published Date: 3/12/2026
Notice
Summary
The FDA is officially pulling the plug on 15 drug approvals because the companies, including Watson Laboratories and others, told the FDA they stopped selling these medicines. This change kicks in on April 13, 2026, but companies can apply again if they want. No money penalties here—just a cleanup to keep things current and clear!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Fifteen Generic Drug Approvals Withdrawn
The FDA is withdrawing approval of 15 abbreviated new drug applications (ANDAs) for listed generic medicines (examples include cimetidine, fluoxetine HCl, famotidine, sotalol HCl, paclitaxel injectable, doxazosin mesylate, gabapentin, bisoprolol fumarate/hydrochlorothiazide, and vinorelbine tartrate) as of April 13, 2026. The applicants told FDA they stopped marketing these products, and products in inventory on April 13, 2026 may still be dispensed until the inventory is depleted or the product expires.
Manufacturers May Refile; No Penalty
The FDA says the withdrawals are "without prejudice to refiling," so applicants may submit new ANDAs again if they choose. The applicants waived their opportunity for a hearing, and the notice describes this action as a cleanup rather than a monetary penalty.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-04796, Privacy Act of 1974; Matching Program
The FCC and USAC are teaming up with HUD to double-check who qualifies for Lifeline and the Affordable Connectivity Program, which help low-income families get affordable internet and phone service. This new computer matching program starts April 13, 2026, runs for 18 months, and aims to keep benefits fair and accurate. If you’re part of these programs, this means better verification but no changes to your current support.
Next: 2026-04800, Self-Regulatory Organizations; CME Securities Clearing Inc.; Notice of Filing of Proposed Rule Change To Modify the CME Securities Clearing Inc. Amended and Restated By-Laws, Board of Directors Charter, Risk Management Committee Charter, Nominating Committee Charter, and Audit Committee Charter
CME Securities Clearing Inc. is updating its rules and committee guidelines to get ready for launching new clearing services. These changes affect the Board of Directors and key committees, making sure everything runs smoothly and safely. The updates don’t signal any immediate cost changes but set the stage for a strong, well-organized future starting soon.